Syndax Pharmaceuticals Inc
Company Profile
Business description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Contact
730 Third Avenue
9th Floor
New YorkNY10017
USAT: +1 781 419-1400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
184
Stocks News & Analysis
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,297.20 | 123.30 | -1.31% |
| CAC 40 | 8,197.77 | 196.55 | -2.34% |
| DAX 40 | 23,878.38 | 759.62 | -3.08% |
| Dow JONES (US) | 48,904.78 | 73.14 | -0.15% |
| FTSE 100 | 10,535.10 | 245.01 | -2.27% |
| HKSE | 25,768.08 | 612.94 | -2.32% |
| NASDAQ | 22,748.86 | 80.64 | 0.36% |
| Nikkei 225 | 56,279.05 | 2,474.34 | -4.21% |
| NZX 50 Index | 13,620.21 | 50.50 | -0.37% |
| S&P 500 | 6,881.62 | 2.74 | 0.04% |
| S&P/ASX 200 | 9,077.30 | 104.40 | -1.14% |
| SSE Composite Index | 4,122.68 | 59.92 | -1.43% |